Effect of continuous recombinant human endostatin pumping combined with TP chemotherapy on serum malignant molecules and angiogenesis molecules in patients with advanced ovarian cancer

摘要

Objective: To study the effect of continuous recombinant human endostatin pumping combinedwith TP chemotherapy on serum malignant molecules and angiogenesis molecules in patientswith advanced ovarian cancer. Methods: 78 patients with advanced ovarian cancer who weretreated in our hospital between July 2011 and December 2015 were selected and divided intoobservation group and control group (n=39) according to the single-blind randomized controlmethod. Before treatment and after 4 cycles of treatment, electrochemical luminescenceimmunity analyzer was used to detect serum tumor marker levels; RIA method was used todetermine serum apoptosis molecule levels; enzyme-linked immunosorbent assay (ELISA)was used to detect the serum angiogenesis molecule levels. Results: Before treatment,differences in serum levels of tumor markers, apoptosis molecules and angiogenesis moleculeswere not statistically significant between two groups of patients (P0.05). After 4 cycles oftreatment, serum carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153),human epididymis protein 4 (HE4), carcinoembryonic antigen (CEA), human chorionicgonadotropin (β-HCG), Bcl-2, Survivin, Bag-1, angiogenin-2 (Ang-2), vascular endothelialgrowth factor (VEGF) and basic fibroblast growth factor (bFGF) levels of observation groupwere significantly lower than those of control group (P0.05) while Bax level was significantlyhigher than that of control group (P0.05). Conclusions: Continuous recombinant humanendostatin pumping combined with TP chemotherapy can decrease the malignant degree ofadvanced ovarian cancer and inhibit angiogenesis.